Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
We review which stablecoins fall under regulatory scrutiny, the regimes that apply, and practical implications for users and providers alike.
19,598 articlesA biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
Nvidia is fueling a bold thesis for H2 2026 as AI infrastructure demand climbs. With data-center momentum and locked-...
Andersen Group surged on surprise Q4 strength and an optimistic outlook. This deep dive explains what drove the rally...
A brutal four-session selloff in Korea’s chip sector erased roughly $900 billion in market value, even as analysts in...
A new ETF aims to monetize the price swings of Rocket Lab and other space names by selling weekly put spreads to fund...
A market strategist argues the AI urge to spend is cooling, transferring momentum from software giants to chipmakers ...
XRP shows a modest rebound but remains below critical resistance, signaling caution rather than a breakout. The marke...
An AI-backed forecast tied to Sam Altman’s ChatGPT points to SpaceX stock climbing into the mid-to-high $200s by end-...
Freddie Mac data show mortgage rates climbed to their highest level in almost four months, pushing the 30-year loan t...
A high pre-tax withdrawal can push Social Security into higher taxation, prolonging Medicare costs and altering retir...
Shay Capital reduced its PureCycle stake in the latest 13F filing, prompting questions about the stock's future. This...
The MORT ETF offers a double-digit yield, but its payout hinges on the health of its mortgage REIT holdings. This art...